[PRESS RELEASE] – DENVER, Jan. 20, 2026 – Kazmira Therapeutics announced the official launch of a first-of-its-kind, prescription-only cannabinoid pharmacy, Kazmira Pharmacy. This licensed and LegitScript-certified 503A compounding pharmacy specializes in pure compounded cannabidiol (CBD) without any trace of tetrahydrocannabinol (THC), the intoxicating component in hemp.
Co-founder and co-CEO Priyanka Sharma, Ph.D., said, "The goal is to move CBD from an over-the-counter product to evidence-based, pharmacy-dispensed medicine. Now, providers can work with their patients to prescribe personalized treatment that is best for their unique health concerns."
Sharma explained that the impact of ultra-pure CBD has been studied on a variety of health conditions, including pain management, anxiety disorders and substance abuse disorders. Prescription-only CBD could make a difference for patients who may not have responded well to other treatments on the market.
The timing for Kazmira's pharmacy is ideal, given that hemp and marijuana laws have been front and center in national debates. In December 2025, President Donald Trump signed an executive order, directing the U.S. Attorney General to reschedule cannabis to Schedule III drug. And in November 2025, Trump signed legislation that will ban over-the-counter products that contain more than 0.4 milligrams of THC starting in November 2026.
"Kazmira is not another CBD company reacting to regulatory change. We have an intentional, infrastructure-first health care launch that demonstrates how CBD can be integrated into clinical care without relying on wellness loopholes, retail distribution, or unapproved drug claims," Sharma said. "As scrutiny increases and legacy hemp models face pressure, health care stakeholders need clarity on what survives the transition. This launch offers a credible blueprint for what the future of CBD looks like when treated as medicine, not loosely-regulated, over-the-counter products."
Gautham Oroskar, M.D., a medical adviser at Kazmira Therapeutics, believes the model will improve clinical adoption of CBD as a medical treatment.
"When you take intoxication, impairment and drug-testing concerns off the table, physicians can evaluate how their patients respond to CBD the same way they evaluate any other therapeutic compound," he said. "It becomes a therapeutic tool in their toolkit with a defined mechanism of action, not a supplement with weak clinician oversight."
Kazmira Pharmacy is LegitScript health care certified, a widely recognized standard for health care compliance, transparency and patient safety. The certification validates Kazmira's commitment to pharmacy compliance, patient safety and regulatory standards in CBD compounding. With LegitScript certification secured, Kazmira is positioned to unlock high-value strategic partnerships that require verified health care compliance, enabling sustainable growth at scale.
While initially launching only in Colorado, the pharmacy is structured to expand into additional states. Kazmira is working with state pharmacy boards across the country in licensure, targeting an additional 20 or more states, including Arizona, Florida, Texas and Utah, in 2026.
